Daraxonrasib Nearly Doubles Survival in Previously Treated Metastatic Pancreatic Cancer
A phase III clinical trial has shown that the investigational drug daraxonrasib nearly doubles survival rates for patients with previously treated metastatic pancreatic cancer. The drug targets activated KRAS signaling, offering a potential new standard for second-line treatment.
Why it matters
Pancreatic cancer has a very low survival rate, making this breakthrough in targeted therapy a significant development for oncology and patient care.
The investigational multiselective RAS(ON) inhibitor daraxonrasib may represent a new standard second-line treatment option for patients with metastatic pancreatic ductal adenocarcinoma, according to results from the phase III RASolute 302 trial. In the study, presented by Brian Wolpin, MD, MPH , of Dana-Farber Cancer Institute, at the 2026 ASCO Annual Meeting , daraxonrasib nearly doubled both overall survival and progression-free survival compared with standard chemotherapy while producing fewer serious adverse events ( Abstract LBA5 ) .
The report is based on clinical trial data presented at a medical conference, maintaining a scientific and objective tone.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in